Free Trial
NASDAQ:PULM

Pulmatrix Q3 2024 Earnings Report

Pulmatrix logo
$1.36 +0.01 (+1.12%)
As of 05/22/2026 04:00 PM Eastern
This is a fair market value price provided by Massive. Learn more.

Pulmatrix EPS Results

Actual EPS
-$0.71
Consensus EPS
N/A
Beat/Miss
N/A
One Year Ago EPS
N/A

Pulmatrix Revenue Results

Actual Revenue
$0.37 million
Expected Revenue
N/A
Beat/Miss
N/A
YoY Revenue Growth
N/A

Pulmatrix Announcement Details

Quarter
Q3 2024
Time
Before Market Opens
Conference Call Date
Friday, November 8, 2024
Conference Call Time
7:00AM ET

Upcoming Earnings

Pulmatrix's Q2 2026 earnings is estimated for Wednesday, August 12, 2026, based on past reporting schedules

Pulmatrix Earnings Headlines

Pulmatrix Inc : PULM
Read now. Do not delete. You’ve been warned.
Three Nobel Prize Winners expose this once-in-a-generation wealth shift: “Don’t Say I Didn’t Warn You” Porter Stansberry exposes how the convergence of three immense forces is about to rewrite everything about the American way of life: how you work, save, invest… it’s all about to change.tc pixel
See More Pulmatrix Headlines
Get Earnings Announcements in your inbox

Want to stay updated on the latest earnings announcements and upcoming reports for companies like Pulmatrix? Sign up for Earnings360's daily newsletter to receive timely earnings updates on Pulmatrix and other key companies, straight to your email.

About Pulmatrix

Pulmatrix (NASDAQ:PULM) is a clinical-stage biopharmaceutical company dedicated to developing inhaled therapies for patients suffering from respiratory diseases. The company’s proprietary iSPERSE® dry-powder formulation platform produces fine microparticles optimized for deep-lung delivery, rapid absorption and consistent dosing, addressing challenges often encountered with traditional inhalation approaches.

Among Pulmatrix’s lead programs is PUR1900, an inhaled therapy designed to treat pulmonary fungal infections such as allergic bronchopulmonary aspergillosis (ABPA). Another key candidate, PLX100, is being investigated for pulmonary sarcoidosis, a chronic inflammatory disease of the lungs. Both programs have progressed through preclinical and early clinical stages, demonstrating favorable tolerability profiles and the potential to reduce systemic side effects.

Founded in 2005 and headquartered in Lexington, Massachusetts, Pulmatrix combines formulation science with pulmonary pharmacology to advance its pipeline. The company collaborates with leading academic institutions and clinical research centers across the United States to conduct studies in diverse patient populations, leveraging its R&D infrastructure to support efficient development pathways.

Pulmatrix’s leadership team brings extensive experience in respiratory drug development and regulatory strategy. Focused on advancing its inhaled therapies through pivotal trials and strategic partnerships, the company aims to expand its portfolio into additional acute and chronic respiratory conditions, ultimately improving patient outcomes and quality of life.

View Pulmatrix Profile